Systemic antifungals to treat onychomycosis in children: A systematic review

Pediatric Dermatology

Volumn 30, Issue 3, 2013, Pages 294-302

  Gupta, Aditya K ^a,b   Paquet, Maryse ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; CICLOPIROX; CICLOPIROXOLAMINE; CLOTRIMAZOLE; FLUCONAZOLE; GRISEOFULVIN; IMIDAZOLE; ITRACONAZOLE; MICONAZOLE; TERBINAFINE;

AGE DISTRIBUTION; AGRANULOCYTOSIS; ANOREXIA; ANTIMICROBIAL THERAPY; ATAXIA; BODY WEIGHT; CHILD CARE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DERMATOPHYTOSIS; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FATIGUE; FINGER NAIL; GASTRITIS; HEADACHE; HUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL; PUBLICATION; PUSTULE; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; URTICARIA;

AGE FACTORS; ANTIFUNGAL AGENTS; CHILD; HUMANS; ONYCHOMYCOSIS; REMISSION INDUCTION;

EID: 84876932693     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/pde.12048     Document Type: Review

References (38)

1. Gupta AK, Chang P, Del Rosso JQ, et al. Onychomycosis in children: prevalence and management. Pediatr Dermatol 1998; 15: 464-471. (Pubitemid 29006184)
2. Welsh O, Vera-Cabrera L, Welsh E,. Onychomycosis. Clin Dermatol 2010; 28: 151-159.
3. Canadian Paediatric Society. Antifungal agents for common paediatric infections. Can J Infect Dis Med Microbiol 2008; 19: 15-18.
4. Novartis Pharmaceuticals Corporation. Lamisil tablets (terbinafine) label information 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 020539s021lbl.pdf
5. Novartis Pharmaceuticals Corporation. Lamisil oral granules (terbinafine) label information 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2012/022071s007lbl.pdf
6. Ortho-McNeil-Janssen Pharmaceuticals. Sporanox capsules (itraconazole) label information 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2012/020083s048s049s050lbl.pdf
7. Centocor Ortho Biotech. Sporanox oral solution (itraconazole) label information 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 020657s028lbl.pdf
8. Pfizer. Diflucan tablets (fluconazole) label information 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/019949s055,019950s059, 020090s038lbl.pdf
9. Novartis Consumer Health. Gris-PEG tablets (griseofulvin ultramicrosize) label information 2010. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2010/050475s054lbl.pdf
10. Assaf RR, Elewski BE,. Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. J Am Acad Dermatol 1996; 35 (2 Pt 1): 216-219.
11. Ginter G,. Mycoses in children: systemic treatment. Acta Dermatovenerol Alp Panonica Adriat 1998; 7: 101-105.
12. Ginter-Hanselmayer G, Weger W, Smolle J,. Onychomycosis: a new emerging infectious disease in childhood population and adolescents. Report on treatment experience with terbinafine and itraconazole in 36 patients. J Eur Acad Dermatol Venereol 2008; 22: 470-475. (Pubitemid 351436919)
13. Gupta AK, Nolting S, de Prost Y, et al. The use of itraconazole to treat cutaneous fungal infections in children. Dermatology 1999; 199: 248-252.
14. Jones TC,. Overview of the use of terbinafine (Lamisil) in children. Br J Dermatol 1995; 132: 683-689.
15. Heikkilä H, Stubb S,. Onychomycosis in children: treatment results of forty-seven patients. Acta Derm Venereol 2002; 82: 484-485. (Pubitemid 36140264)
16. Huang PH, Paller AS,. Itraconazole pulse therapy for dermatophyte onychomycosis in children. Arch Pediatr Adolesc Med 2000; 154: 614-618. (Pubitemid 30387385)
17. Romano C, Papini M, Ghilardi A, et al. Onychomycosis in children: a survey of 46 cases. Mycoses 2005; 48: 430-437. (Pubitemid 43942689)
18. Aguilar C, Mueller KK,. Reversible agranulocytosis associated with oral terbinafine in a pediatric patient. J Am Acad Dermatol 2001; 45: 632-634. (Pubitemid 32917266)
19. Aihara Y, Mori M, Yokota S,. Successful treatment of onychomycosis with fluconazole in two patients with hyperimmunoglobulin E syndrome. Pediatr Dermatol 1996; 13: 493-495. (Pubitemid 27009819)
20. Aly R, Hafeez ZH, Rodwell C, et al. Int J Dermatol 2002; 41: 357-359.
21. Baran R,. Proximal subungual Candida onychomycosis. An unusual manifestation of chronic mucocutaneous candidosis. Br J Dermatol 1997; 137: 286-288. (Pubitemid 27333368)
22. Desgarennes MD, Godoy MR, Palencia AB,. Therapeutic efficacy of terbinafine in the treatment of three children with tinea tonsurans. J Am Acad Dermatol 1996; 35: 114-116. (Pubitemid 26231339)
23. Elewski BE,. Trichophyton rubrum onychomycosis in a 17-year-old girl. Cutis 1997; 60: 253-254. (Pubitemid 127473336)
24. Falcõn CS, Falcõn MDMS, Ceballos JD, et al. Onychomycosis by Chaetomium spp. Mycoses 2009; 52: 77-79.
25. Friedlander SF,. A 14-year-old boy with onychomycosis. Adv Stud Med 2005; 5: S629-S633. (Pubitemid 41060106)
26. Gianni C, Cerri A, Capsoni F, et al. Recurrent proximal white subungual onychomycosis associated with a defect of the polymorphonuclear chemotaxis. Eur J Dermatol 1999; 9: 390-392. (Pubitemid 29366891)
27. Goulden V, Goodfield MJD,. Treatment of childhood dermatophyte infections with oral terbinafine. Pediatr Dermatol 1995; 12: 53-54.
28. Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997; 36 (3 Pt 1): 395-402. (Pubitemid 27131962)
29. Gupta AK, Adam P, Hofstader SL,. Itraconazole oral solution for the treatment of onychomycosis. Pediatr Dermatol 1998; 15: 472-474. (Pubitemid 29006185)
30. Jacobs AH, O'Connell BM,. Tinea in tiny tots. Am J Dis Child 1986; 140: 1034-1038. (Pubitemid 16022198)
31. Khurana VK, Gupta RK, Pant L, et al. Trichophyton rubrum onychomycosis in an 8-week-old infant. Indian J Dermatol Venereol Leprol 2011; 77: 625.
32. Shmunes E,. Onychomycosis in a 14-month-old child. South Med J 1976; 69: 1097-1098.
33. Tay YK, Seow CS,. What syndrome is this? Chronic mucocutaneous candidiasis, Pediatr Dermatol 2001; 18: 353-355.
34. Tosti A, Piraccini BM, Vincenzi C,. Itraconazole in the treatment of two young brothers with chronic mucocutaneous candidiasis. Pediatr Dermatol 1997; 14: 146-148. (Pubitemid 27193845)
35. Ungpakorn R, Reangchainam S, Kullavanijaya P,. Onychomycosis in a 2-year-old child successfully treated with oral terbinafine. J Am Acad Dermatol 1998; 39 (4 Pt 1): 654-655. (Pubitemid 28465897)
36. Gupta AK, Ryder JE, Johnson AM,. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004; 150: 537-544. (Pubitemid 38446311)
37. Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol 2012; 66: 494-502.
38. González U, Seaton T, Bergus G, et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev 2007;(4): CD004685.